KIR2DL3 and glioblastoma: However, donor 59’s KIR2DL1, KIR2DL2, and KIR2DL3 licensed NK cells encountering HLA-group C1 ligands C*05:01 (present in P3 cells) or licensed NK cells from donors 59 and 35 encountering C*07:01 alleles also present in 2012-018 cells might have “calibrated” the killing potency against the GBM cells in serum-containing medium (Table 2; Figures 4B,C,F).